Chromosomal instability and a deregulated cell cycle are intrinsic features of high‐risk gastrointestinal stromal tumours with a metastatic potential

Patients with localised, high‐risk gastrointestinal stromal tumours (GIST) benefit from adjuvant imatinib treatment. Still, approximately 40% of patients relapse within 3 years after adjuvant therapy and the clinical and histopathological features currently used for risk classification cannot precis...

Full description

Bibliographic Details
Main Authors: Heidi Maria Namløs, Ksenia Khelik, Sigve Nakken, Daniel Vodák, Eivind Hovig, Ola Myklebost, Kjetil Boye, Leonardo A. Meza‐Zepeda
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Molecular Oncology
Subjects:
Online Access:https://doi.org/10.1002/1878-0261.13514